Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 5, No 1 (2013) Dopamine dysregulation syndrome in Parkinson’s disease Abstract  similar documents
A V Nikitina, Natalia Vladimirovna Fedorova
"... therapy. According to the data available in the literature, DDS develops in 3-4% of the Parkinson’s ..."
 
Vol 5, No 1 (2013) Practical aspects of the use of extended-release ropinirole (requip modutab) in the treatment of Parkinson’s disease Abstract  similar documents
Oleg Semenovich Levin, V K Datiyeva
"... . The starting dose of the drug was 2 mg/day in all the cases. Then it was increased once weekly until ..."
 
Vol 6, No 3 (2014) Myofascial pain: from Virchow's to our days Abstract  similar documents
I. V. Egorov
"... drugs and further to the increase of their doses because the treatment is ineffective. Modern-day ..."
 
Vol 5, No 2 (2013) Current possibilities of therapy for sleep disorders in Parkinson’s disease Abstract  similar documents
Marina Romanovna Nodel
"... to antiparkinsonian drugs, melatonin was given in a dose of 3 mg/day. The efficiency of the therapy was evaluated ..."
 
Vol 3, No 3 (2011) Neuropsychiatrie disorders in Parkinson's disease and their correction with the MAO-B inhibitor rasagiline (Azilect®) Abstract  similar documents
M R Nodel
"... Parkinson's disease (PD) is a multisystemic neurodegenerative disease with a broad spectrum ..."
 
Vol 4, No 2 (2012) Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease Abstract  similar documents
S N Illarioshkin
"... receptor agonists (DRA) remains the leading pharmacotherapeutic strategy for Parkinson’s disease (PD ..."
 
Vol 5, No 2 (2013) Neuropsychological syndromes in patients with Parkinson’s disease after deep electric stimulation of pallidar complex structures Abstract  similar documents
Yu V Mikadze, Irina Igorevna Titkova, A O Gushcha, V M Tyurnikov
"... The paper provides the results of neuropsychological examinations in 10 patients with Parkinson’s ..."
 
Vol 7, No 3 (2015) Experience in using levodopa-benserazide Abstract  similar documents
Elena Anatolyevna Katunina, Yu. N. Bezdolnyi, E. A. Malykhina, N. V. Titova
"... Levodopa remains the most effective drug for the treatment of Parkinson's disease. The paper ..."
 
Vol 9, No 1 (2017) Comparison of the efficacy of the multimodal serotonergic antidepressants trazodone and vortioxetine in the treatment of patients with endogenous depression: A meta-analysis of double-blind randomized placebo-controlled trials Abstract  similar documents
D. S. Danilov
"... in Group 1: a) therapy with trazodone at an average dose of about 300 mg/day significantly more frequently ..."
 
Vol 4, No 1 (2012) Sleep and awakening disorders in Parkinson’s disease: comprehensive approach to therapy Abstract  similar documents
Marina Romanovna Nodel
"... and awakening disorders in patients with Parkinson’s disease (PD). It covers the current views of the role ..."
 
Vol 8, No 4 (2016) HYPERSOMNIA AND CIRCADIAN DISTURBANCES IN PARKINSON’S DISEASE Abstract  similar documents
M. R. Nodel
"... studied symptoms of Parkinson’s disease (PD). It manifests as constant excessive sleepiness during the day ..."
 
Vol 3, No 1 (2011) Sleep disorders in Parkinson's disease Abstract  similar documents
Marina Romanovna Nodel', Marina Romanovna Nodel
"... of Parkinson's disease (PD). Objective: to specify the clinical features of sleep disorders in patients with PD ..."
 
Vol 6, No 1 (2014) Apathy in Parkinson's disease patients Abstract  similar documents
M. R. Nodel
"... pathy in Parkinson's disease (PD) patients is one of the least studied manifestations of a broad ..."
 
Vol 4, No 1 (2012) Sustained-release pramipexole in the treatment of Parkinson’s disease Abstract  similar documents
Natalia Vladimirovna Fedorova
"... for dopaminergic deficiency in Parkinson’s disease (PD). Since 1996, pramipexole has been used to treat early ..."
 
Vol 3, No 3 (2011) Use of amelotex to treat patients with acute musculoskeletal pain in the back and grade 1 essential hypertension Abstract  similar documents
E V Podchufarova, N N Yakhno
"... of the safety and efficacy of amelotex (meloxicam injectable dosage form) in an intramuscular dose of 15 mg/day ..."
 
Vol 6, No 3 (2014) Current therapy for Parkinson's disease Abstract  similar documents
A. V. Obukhova
"... The main goal of therapy for Parkinson's disease (PD) is to correct dopamine deficiency ..."
 
Vol 3, No 3 (2011) Poststroke cognitive impairments and their therapy with ceraxon Abstract  similar documents
N V Shakhparonova, A S Kadykov, E Kashina
"... with citicoline (ceraxon) in a dose of 500 or 1000 mg/day caused positive changes in the neurody-namic ..."
 
Vol 7, No 4 (2015) Some aspects of treatment for cognitive impairments. Cyticolin: pharmacological characteristics, possible benefits, aspects of use Abstract  similar documents
N. V. Trofimova, I. S. Preobrazhenskaya
"... в дозе 2 г/сут у пожилых пациентов с клинической картиной спутанности 68 О Б З О Р Ы сознания ..."
 
Vol 2, No 2 (2010) Clinical electroencephalographic criteria for the efficacy of rispolept therapy in children with Tourette's syndrome Abstract  similar documents
Valeri Petrovich Zykov, S A Kabanova
"... years who took rispolept in a dose of 2-3 mg/day. The clinical and electroencephalographic assessment ..."
 
Vol 4, No 3 (2012) Clinical experience with requip modutab Abstract  similar documents
Denis Valeryevich Zakharov, V A Mikhailov
"... of therapy for extensive-stage Parkinson’s disease (PD) and to correct motor fluctuations and drug-induced ..."
 
Vol 1, No 3-4 (2009) TREATMENT FOR ACUTE NONSPECIFIC BACK PAIN IN OUTPATIENT PRACTICE Abstract  similar documents
O N Gerasimova, Vladimir Anatol'evich Parfenov, O N Gerasimova, Vladimir Anatolyevich Parfenov
"... techniques. The patients took movalis in a dose of 15 mg/day orally or 15 mg/day intramuscularly for up to 5 ..."
 
Vol 9, No 3 (2017) Screening for non-motor symptoms in Parkinson's disease using the NMSQuest scale Abstract  similar documents
A. A. Tappakhov, T. E. Popova, T. Ya. Nikolaeva, N. A. Schnaider, M. M. Petrova
"... The clinical picture of Parkinson's disease (PD) includes a wide range of non-motor symptoms (NMS ..."
 
Vol 5, No 2 (2013) The clinical picture of early-stage Parkinson’s disease. errors in the diagnosis of different forms Abstract  similar documents
E N Gubanova, Natalia Vladimirovna Fedorova
"... The paper describes the clinical picture of Parkinson’s disease (PD), by indicating its stages ..."
 
Vol 10, No 4 (2018) Nighttime sleep disorders in patients with daytime sleepiness in Parkinson s disease Abstract  similar documents
M. R. Nodel, K. V. Shevtsova, G. V. Kovrov, N. N. Yakhno
"... Daytime sleepiness is one of the clinically significant non-motor manifestations of Parkinson ..."
 
Vol 3, No 3 (2011) Prevention of Alzheimer's disease Abstract  similar documents
V A Parfenov
"... that mydocalm given in a dose of 300 to 900 mg/day may be effective in treating poststroke spasticity. ..."
 
Vol 1, No 1 (2009) ETORICOXIB: THERAPEUTIC POTENTIAL Abstract  similar documents
A E Karateev, A E Karateev
"... advantages of the drug are its easiness-to-use (once-daily dosing), a wide range of effective doses (from 30 ..."
 
Vol 2, No 3 (2010) Clinical experience with ceraxon used in ischemic stroke Abstract  similar documents
Vladimir Anatolyevich Parfenov, T G Fateyeva, O V Kosivtsova
"... cerebrovascular diseases. The efficiency and safety of Ceraxon intravenously in a dose of2000 mg/day for 10 days ..."
 
Vol 10, No 1S (2018): СПЕЦВЫПУСК: ЭПИЛЕПСИЯ An open-label prospective clinical study of the efficacy and tolerability of brand-name and generic levetiracetam in the monotherapy of focal epilepsy in adults Abstract  similar documents
V. A. Karlov, P. N. Vlasov, I. A. Zhidkova
"... . The  frequency of adverse events was 17.5% for both bLEV and gLEV. The median dose of LEV was 1000 mg/day ..."
 
Vol 5, No 3 (2013) The efficacy of the dopamine agonist Rotigotine in the treatment of Parkinson's disease Abstract  similar documents
Marina Romanovna Nodel
"... patch in Parkinson's disease (PD) and discusses the results of clinical trials of Rotigotine in early ..."
 
Vol 4, No 2 (2012) The efficacy and tolerability of paroxetine (adepress), an antidepressant from a group of selective serotonin reuptake inhibitors, in psychoautonomic syndrome within anxiety-depressive disorders Abstract  similar documents
T G Voznesenskaya, N M Fokina
"... (paroxetine) was used in a dose of 10—20 mg/day for 8 weeks. Adverse reactions were observed in one-third ..."
 
Vol 2, No 4 (2010) Experience in using ceretone (choline alfoscerate) in brain concussion Abstract  similar documents
N G Voropay, Ol'ga Borisovna Doronina, B M Doronin, N G Voropai, Olga Borisovna Doronina, B M Doronin
"... sleepiness, anxiety, and bad mood. Thirty-nine patients received intravenous ceretone® in a dose of 1000 mg ..."
 
Vol 7, No 3 (2015) Efficiency of epilepsy treatment in the Moscow Region under the present-day conditions of drug provision Abstract  similar documents
Irina Gennadyevna Rudakova, Yu. A. Belova
"... Region under the present-day conditions of drug provision Rudakova I.G., Belova Yu.A. M.F. Vladimirsky ..."
 
Vol 9, No 4 (2017) Antitumor effects of the combined use of vitamins B1, B6, and B12 Abstract  similar documents
L. V. Stakhovskaya, O. A. Gromova, I. Yu. Torshin, M. V. Filimonova
"... to comprehensively estimate the feasibility and safety of its use, especially at high (therapeutic) doses. The paper ..."
 
Vol 4, No 3 (2012) Experience in correcting brain edema in cerebral infarction Abstract  similar documents
E V Eliseyev, T Yu Nedorostkova, Sofia Alekseyevna Rumyantseva, V V Afanasyev
"... -lysine aescinate in a daily dose of10 ml in a slow dropwise manner during the first 3 days. Results ..."
 
Vol 2, No 2 (2010) Cervicogenic headache: the specific features of complex therapy with Amelotex and CompligamV Abstract  similar documents
Mariya Lvovna Pospelova
"... in a dose of 15 mg/day for 6 days and CompligamV in a dose of one ampoule for 15 days was conduced in 30 ..."
 
Vol 1, No 2 (2009) VESTIBULAR VERTIGO. EXPERIENCE IN USING BETAVER Abstract  similar documents
Vladimir Anatol'evich Parfenov, O V Abdulina, Vladimir Anatolyevich Parfenov, O V Abdulina
"... ). All the examinees took betaver in a dose of 48 mg/day for 30 days. Betaver treatment resulted ..."
 
Vol 4, No 1 (2012) Experience in using sulpiride in non-psychotic endogenous depressive-hypochondriacal disorders Abstract  similar documents
Nina Arkadyevna Tyuvina, V. V. Balabanova, E M Goncharova
"... in an initial dose of50—100 mg/day; the dose was, if required, increased up to 400—600 mg/day. Results. After 2 ..."
 
Vol 1, No 3-4 (2009) RUSSIAN OBSERVATIONAL SURVEY OF THE SHORT-TERM EFFICACY AND TOLERABILITY OF SUSTAINED-RELEASE SODIUM VALPROATE (DEPAKINE CHRONOSPHERA®) AS A FIRST-LINE DRUG IN THE TREATMENT OF EPILEPSY Abstract  similar documents
Elena Dmitrievna Belousova, A Yu Ermakov, Elena Dmitriyevna Belousova, A Yu Ermakov
"... . The starting dose of Depakine Chronosphera® was 10-15 mg/day; the mean therapeutic dose was 20-30 mg/kg/day ..."
 
Vol 2, No 4 (2010) Depression in Parkinson's disease Abstract  similar documents
Marina Romanovna Nodel', Marina Romanovna Nodel
"... Parkinson's disease (PD) is a multisystemic neurodegenerative disease with a wide spectrum ..."
 
Vol 9, No 1 (2017) The genetic basis of Parkinson's disease Abstract  similar documents
A. A. Tappakhov, T. E. Popova, T. Ya. Nikolaeva, P. I. Gurieva, N. A. Shnaider, M. M. Petrova, M. R. Sapronova
"... Parkinson's disease (PD) is a multifactorial disease that develops in the presence of both genetic ..."
 
Vol 3, No 4 (2011) Parkinson's disease fatigability and its correction with the dopamine receptor agonist pramipexole Abstract  similar documents
Marina Romanovna Nodel
"... Fatigability is a common nonmotor symptom in Parkinson's disease (PD), which worsens quality ..."
 
Vol 6, No 4 (2014) Nondrug therapy in the combination rehabilitation of patients with Parkinson’s disease Abstract  similar documents
V. L. Golubev, A. B. Kamakinova
"... Non-drug rehabilitation in Parkinson’s disease (PD) has recently attracted the increasing ..."
 
Vol 1, No 2 (2009) NERVOUS AND MENTAL DISORDERS OF PARKINSON'S DISEASE Abstract  similar documents
Marina Romanovna Nodel', N N Yakhno, Marina Romanovna Nodel, N N Yakhno
"... Parkinson's disease (PD) is a multisystemic neurodegenerative disease involving different mediator ..."
 
Vol 9, No 1 (2017) The clinical features, diagnosis, and treatment of cognitive impairments in Parkinson's disease Abstract  similar documents
G. N. Akhmadeeva, R. V. Magzhanov, G. N. Tayupova, A. R. Baitimerov
"... with Parkinson's disease (PD) and gives their characteristics and epidemiology, the specific features ..."
 
Vol 3, No 1 (2011) Current aspects of the epidemiology and treatment of chronic brain ischemiain the presence of essential hypertension (results of the CALIPSO program) Abstract  similar documents
Elena Igorevna Chukanova, Elena Igorevna Chukanova
"... . The patients received dropwise intravenous Cavinton as infusions within the first week (25 mg on days 1 to 4 ..."
 
Vol 1, No 1 (2009) THERAPY FOR EPILEPSY IN MIDDLE-AGED AND ELDERLY PATIENTS Abstract  similar documents
P N Vlasov, O V Andreeva, P N Vlasov, O V Andreyeva
"... , a frequent combination with concomitant mental and somatic diseases, and a relative efficacy of small-dose ..."
 
Vol 1, No 2 (2009) ACUTE BACK PAIN IN THE OUTPATIENT SETTING AND ITS TREATMENT WITH MYDOCALM AND MIRLOX Abstract  similar documents
S V Verbitskaya, Vladimir Anatol'evich Parfenov, K N Borisov, A V Verbitskaya, Vladimir Anatolyevich Parfenov, K N Borisov
"... back pain, 30 patients were treated with mirlox (7,5- 15 mg/day) and 30 patients received mirlox ..."
 
Vol 2, No 3 (2010) Treatment of parkinson's disease ata young age Abstract  similar documents
Dmitry Valeryevich Artemyev
"... and middle-aged patients. It is stressed that early-onset Parkinson's disease (PD) shows a number ..."
 
Vol 7, No 1 (2015) Diagnosis and treatment of dizziness in outpatient practice Abstract  similar documents
L. M. Antonenko, N. V. Bestuzheva, V. A.
 Parfenov
"... , betaserc) were most commonly used in a dose of 48 mg/day to treat vestibular vertigo. It gives the results ..."
 
Vol 3, No 4 (2011) Ketorolac in clinical practice Abstract  similar documents
Andrei Evgenyevich Karateev
"... permits reductions in the dose of opioids and in the risk of their adverse reactions ..."
 
1 - 50 of 555 Items 1 2 3 4 5 6 7 8 9 10 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)